Related Experiment Video
Updated: Jun 27, 2025

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
Published on: January 29, 2018
Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in
Abstract:
Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein. and is ultimately refractory to therapeutic approaches. SS18::SSX alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, leading to the degradation of canonical (cBAF) complex and amplified presence of an SS18::SSX-containing non-canonical BAF (ncBAF or GBAF) that drives an SS-specific transcription program and tumorigenesis. We demonstrate that SS18::SSX activates the SUMOylation program and SSs are sensitive to the small molecule SAE1/2 inhibitor, TAK-981. Mechanistically, TAK-981 de-SUMOylates the cBAF subunit SMARCE1, stabilizing and restoring cBAF on chromatin, shifting away from SS18::SSX-ncBAF-driven transcription, associated with DNA damage and cell death and resulting in tumor inhibition across both human and mouse SS tumor models. TAK-981 synergized with cytotoxic chemotherapy through increased DNA damage, leading to tumor regression. Targeting the SUMOylation pathway in SS restores cBAF complexes and blocks the SS18::SSX-ncBAF transcriptome, identifying a therapeutic vulnerability in SS, positioning the in-clinic TAK-981 to treat SS.
Insights
Targeting the SUMOylation pathway with TAK-981 inhibits synovial sarcoma (SS) by restoring chromatin remodeling complexes. This approach shows promise for treating SS and synergizes with chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein, leading to resistance to current therapies.
- SS18::SSX alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, promoting tumorigenesis through a specific transcriptional program.
Purpose of the Study:
- To investigate the therapeutic potential of targeting the SUMOylation pathway in SS.
- To elucidate the mechanism of action of the SAE1/2 inhibitor TAK-981 in SS.
Main Methods:
- Treatment of human and mouse SS models with TAK-981.
- Analysis of chromatin remodeling complex composition and transcriptional changes.
- Assessment of DNA damage and cell death induction.
- Evaluation of synergistic effects with cytotoxic chemotherapy.
Main Results:
- SS18::SSX activates SUMOylation; SSs are sensitive to TAK-981.
- TAK-981 de-SUMOylates SMARCE1, restoring canonical BAF (cBAF) complexes.
- Restored cBAF shifts transcription away from the SS18::SSX-driven program, inducing DNA damage and cell death.
- TAK-981 demonstrated tumor inhibition in SS models and synergized with chemotherapy for tumor regression.
Conclusions:
- Targeting the SUMOylation pathway represents a therapeutic vulnerability in SS.
- TAK-981 restores cBAF complexes and blocks oncogenic transcription, offering a novel treatment strategy.
- The in-clinic drug TAK-981 is positioned as a potential therapy for synovial sarcoma.
More Related Videos
09:21Saccharomyces cerevisiae Metabolic Labeling with 4-thiouracil and the Quantification of Newly Synthesized mRNA As a Proxy for RNA Polymerase II Activity
Published on: October 22, 2018
08:29SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
Published on: November 1, 2019
Related Concept Videos
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
RNA Splicing
Cytoskeletal Accessory Proteins
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Regulation of Expression at Multiple Steps
Abnormal Proliferation